Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

2009 2008 2009 2008 ---- ---- ---- ---- Cost-sharing of Regeneron VEGF Trap-Eye development expenses $9.7 $5.7 $27.5 $18.3 Recognition of deferred revenue related to up-front and non-substantive milestone payments 2.5 3.3 7.4 9.9 --- --- --- --- Total Bayer HealthCare contract research & development revenue $12.2 $9.0 $34.9 $28.2 ===== ==== ===== =====

In periods when the Company recognizes VEGF Trap-Eye development expenses that the Company incurs under the collaboration with Bayer HealthCare, the Company also recognizes, as contract research and development revenue, the portion of those VEGF Trap-Eye development expenses that is reimbursable by Bayer HealthCare. The Company incurred higher VEGF Trap-Eye development expenses under the collaboration for the three and nine months ended September 30, 2009, compared to the same period in 2008, primarily in connection with the collaboration's clinical development programs in wet AMD, DME, and CRVO.

Research Progress Payment

In July 2009, the Company received a $20.0 million substantive milestone payment from Bayer HealthCare in connection with the dosing of the first patient in a Phase 3 trial of VEGF Trap-Eye in CRVO. The payment was recognized in revenues as a research progress payment for the three and nine months ended September 30, 2009.

Technology Licensing Revenue

Regeneron has entered into non-exclusive license agreements with AstraZeneca and Astellas that allow those companies to utilize VelocImmune® technology in their internal research programs to discover human monoclonal a
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated ... of non-constipating irritable bowel syndrome (IBS). Top-line results ... times daily produced a statistically significant improvement in global ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer of ... first fiscal quarter ended September 30, 2009, compared with $2,001,896 ... 2.2%. , The first quarter of fiscal 2010 produced operating ... for the first quarter of fiscal 2009. The net loss ...
Cached Medicine Technology:Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 5Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... have made a brain-related discovery that could revolutionize ... This discovery opens up the possibility that environmental ... specific brain activity that the researchers have identified ... Journal of Neuroscience has just published a ... associate professor of psychology and his doctoral student ...
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... death risk, study finds , WEDNESDAY, Aug. 12 (HealthDay ... early non-invasive ventilation after a breathing tube has been ... die, a Spanish study has found. , The study ... had high levels of carbon dioxide in their blood, ...
... , GUANGZHOU, China, Aug. 13 ... Medicine" or "the Company"), a developer,and a leading distributor ... (TCM), nutritional and dietary supplements, and,medical devices and medical ... Second Quarter 2009 Highlights:, ...
... From cranky bosses to incompetent coworkers, traffic jams, inconsiderate drivers, ... way through the typical work day in big cities are enough ... , Tanna Marshall, a holistic health consultant and ... natural health practitioner, offers a collection of tips and advice to ...
... , , THOUSAND OAKS, ... today will summarize data from the submitted Biologic License Applications (BLAs) ... the prevention and treatment of bone loss in breast and prostate ... Food and Drug Administration,s (FDA) Advisory Committee for Reproductive Health Drugs ...
... , NEW YORK, Aug. 13 Terraboost -- ... announced a new program today to provide complimentary touch-free hand ... mitigate risk related to H1N1 swine flu and other disease-causing ... ) , , With the ...
... , ... In September of 2008 SpeechNutrients introduced the ... nutritional support for children with apraxia and speech challenges. A ... Health and Medicine reported that 181 children with verbal apraxia taking ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:China Medicine Announces Second Quarter 2009 Results 2Health News:China Medicine Announces Second Quarter 2009 Results 3Health News:China Medicine Announces Second Quarter 2009 Results 4Health News:China Medicine Announces Second Quarter 2009 Results 5Health News:China Medicine Announces Second Quarter 2009 Results 6Health News:China Medicine Announces Second Quarter 2009 Results 7Health News:China Medicine Announces Second Quarter 2009 Results 8Health News:China Medicine Announces Second Quarter 2009 Results 9Health News:China Medicine Announces Second Quarter 2009 Results 10Health News:China Medicine Announces Second Quarter 2009 Results 11Health News:China Medicine Announces Second Quarter 2009 Results 12Health News:China Medicine Announces Second Quarter 2009 Results 13Health News:China Medicine Announces Second Quarter 2009 Results 14Health News:'Living Peacefully in a Big City': Natural Health Practitioner Offers Advice on Maintaining Sanity, Health and Happiness 2Health News:'Living Peacefully in a Big City': Natural Health Practitioner Offers Advice on Maintaining Sanity, Health and Happiness 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 2Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 4Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 5Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 6Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 7Health News:Terraboost Unveils Free H1N1 Risk Mitigation Product 2Health News:Terraboost Unveils Free H1N1 Risk Mitigation Product 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 2Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: